Ileana Tandron, MD
Endocrinology, Diabetes & Metabolism · Slidell, LANPI 1083614879
Payments from drug & device makers
Across 2,176 payments — averaging $242.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$322K
- Novo Nordisk$200K
- Grifols USA, LLC$520
- Abbott$443
- Lilly USA, LLC$380
- Boehringer Ingelheim$355
- plus $4K from 34 others
Across 1,251 payments — averaging $206.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$258K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 1,627 | $321,878 |
| Novo Nordisk | 242 | $199,561 |
| Grifols USA, LLC | 25 | $520 |
| Abbott | 28 | $443 |
| Lilly USA, LLC | 24 | $380 |
| Boehringer Ingelheim | 24 | $355 |
| AbbVie | 20 | $342 |
| Amgen(2 entities) | 19 | $327 |
| IBSA Pharma Inc. | 17 | $302 |
| AstraZeneca | 17 | $273 |
| Kowa Pharmaceuticals America, Inc. | 15 | $262 |
| Jazz Pharmaceuticals Inc. | 13 | $260 |
| Amneal Pharmaceuticals LLC | 15 | $254 |
| Lifescan, Inc. | 16 | $248 |
| Amarin Pharma, Inc. | 9 | $159 |
| Dexcom, Inc. | 2 | $150 |
| Sanofi-aventis U.S. LLC | 9 | $148 |
| Xeris Pharmaceuticals, Inc. | 7 | $141 |
| Mylan Specialty L.p. | 9 | $140 |
| Merck | 6 | $95 |
| Bayer | 5 | $87 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Embecta Corp. | 3 | $50 |
| Novartis | 2 | $35 |
| BD | 2 | $32 |
| Shire North American Group Inc | 2 | $29 |
| Johnson & Johnson | 2 | $27 |
| Kyowa Kirin, Inc. | 1 | $24 |
| BETA Bionics, Inc. | 2 | $23 |
| Corcept Therapeutics | 1 | $22 |
| GSK | 1 | $21 |
| Insulet Corporation | 1 | $20 |
| Mannkind Corporation | 1 | $20 |
| Rochester Medical Corporation | 1 | $17 |
| Inogen, Inc. | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Medtronic | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Ascendis Pharma Endocrinology Inc | 1 | $13 |
| Eisai Inc. | 1 | $13 |
How this compares
$526,784 in reported general payments places this provider in the 90th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Slidell
- Madelyn WiegandSlidell$11K
- Tuan Huy TranMetairie$2M
- Harold MillerHammond$1.1M
- Timothy GilbertBaton Rouge$985K
- Justin FontenotLafayette$905K
- Vivian FonsecaNew Orleans$700K
- Frank GreenwayBaton Rouge$669K
- Abdul KhanHammond$587K
- Jonathan WiseMetairie$463K
- Marideli ScanlanMarrero$446K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.